ANKH and neoplasm: Notably, the extended i.t. retention of the mANK-101 complex significantly enhanced antitumor efficacy, as all 5 mice treated with mANK-101 had tumor regressions on day 28, while tumors in free mIL-12-ABP–treated animals exceeded the 2000 mm3 humane endpoint by day 23 (Figure 2B).